In its 2014 Actavis v. FTC decision, the Supreme Court held that settlement of a Hatch-Waxman patent suit may violate antitrust law if the patent owner makes a “large, unexplained payment” to an alleged infringer. Even after more than four years, judges, lawyers, and drug companies still struggle with complicated evidentiary and economic questions raised by this landmark decision. Peter Rankin is a panelist during this seminar.
For more information on this event, click here.
Evidence requirements for orphan drugs
CRA’s Life Sciences Practice focuses on global policy, commercialization, and market access issues dedicated to orphan drug issues, including orphan evidence...